NASDAQ:PRTO

Proteon Therapeutics - PRTO Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $3.44
▼
$3.57
50-Day Range: $0.84
▼
$25.13
52-Week Range: $0.22
▼
$3.94

Volume: 26,072 shs
Average Volume: 1.11 million shs
Market Capitalization: $76.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Proteon Therapeutics (NASDAQ:PRTO) Stock

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Receive PRTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRTO Stock News Headlines

June 15, 2022 | finance.yahoo.com

ProthioneTM Capsules Reduced Time to COVID-19 Clinical Resolution and Decreased Viral Load in Phase II Clinical Trial

June 3, 2022 | thestreet.com

Bristol-Myers To Buy Turning Point Therapeutics In $4.1 Billion Oncology Deal

May 27, 2022 | bizjournals.com

Flagship Pioneering launches protein startup with $75M

May 30, 2021 | sg.finance.yahoo.com

Worldwide Agricultural Lubricants Industry to 2025 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com

March 19, 2021 | au.finance.yahoo.com

Fed boosts US growth forecast to 6.5% this year

March 19, 2021 | au.finance.yahoo.com

Unseen for two weeks, Tanzanian leader sends 'greetings': deputy

March 19, 2021 | sg.finance.yahoo.com

U.S. House passes bill that aims to advance Equal Rights Amendment

March 19, 2021 | ca.finance.yahoo.com

After 17-month layoff, Artur Beterbiev 'ready to perform' vs. Adam Deines

September 9, 2020 | finance.yahoo.com

DuPont Animal Nutrition to Partner with Proteon Pharmaceuticals in the Poultry Industry

December 10, 2019 | www.bloomberg.com

Moore Kuehn, PLLC Encourages Liberty Property Trust (LPT), Proteon Therapeutics (PRTO), Ra Pharmaceuticals (RARX), Carolina Tru

November 30, 2019 | finance.yahoo.com

Hedge Funds Watching Proteon Therapeutics Inc (PRTO) From Afar

November 24, 2019 | www.bloomberg.com

Moore Kuehn, PLLC Encourages Vitamin Shoppe, Inc. (VSI), Jagged Peak Energy Inc. (JAG), Proteon Therapeutics, Inc. (PRTO), and

November 21, 2019 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Investigates Proteon Therapeutics, Inc.

October 31, 2019 | www.bloomberg.com

Proteon Therapeutics Inc

October 31, 2019 | www.msn.com

BRIEF-Proteon Therapeutics Posts Q3 $1.5 Million

October 31, 2019 | finance.yahoo.com

Proteon Therapeutics Announces Third Quarter 2019 Financial Results

October 22, 2019 | finance.yahoo.com

Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – DOVA, VSI, PRTO

October 18, 2019 | finance.yahoo.com

SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - PRTO, ROAN, PGNX

October 18, 2019 | finance.yahoo.com

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Proteon Therapeutics, Inc. (NASDAQ CM: PRTO)

October 3, 2019 | finance.yahoo.com

PROTEON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Proteon Therapeutics, Inc. - PRTO

September 26, 2019 | finance.yahoo.com

HLND, UCFC, and TRCB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

September 25, 2019 | finance.yahoo.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Proteon Therapeutics, Inc. with ArTara Therapeutics, Inc. is Fair to PRTO Shareholders

September 25, 2019 | finance.yahoo.com

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Proteon Therapeutics, Inc. (NASDAQ: PRTO) on Behalf of Proteon Shareholders and Encourages Proteon Investors to Contact the Firm

September 24, 2019 | finance.yahoo.com

PRTO, ARTX Shareholder Investigation: Halper Sadeh LLP is Investigating Whether the Sale of These Companies is Fair to Shareholders – PRTO, ARTX

September 24, 2019 | finance.yahoo.com

PROTEON THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger

See More Headlines

Receive PRTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRTO Company Calendar

Last Earnings: 10/31/2019
Today: 8/15/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRTO
CUSIP: N/A
CIK: 1359931
Web: www.proteontherapeutics.com
Phone: 781-890-0102
Fax: N/A
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -118.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.98
Quick Ratio: 5.98

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.06) per share
Price / Book: -57.83

Miscellaneous

Outstanding Shares: 22,179,000
Free Float: N/A
Market Cap: $76.96 million
Optionable: Not Optionable
Beta: 0.60

Key Executives

Mr. Timothy P. Noyes (Age 57)
Pres, CEO & Director
Mr. George A. Eldridge (Age 56)
Sr. VP, CFO, Treasurer & Assistant Sec.
Dr. Steven Keith Burke (Age 58)
Sr. VP & Chief Medical Officer
Mr. Matthew P. Kowalsky (Age 46)
VP of Legal & Sec.
Mr. Bradley J. Hartman (Age 38)
VP of People

Key Competitors

View All Competitors

PRTO Stock - Frequently Asked Questions

How were Proteon Therapeutics' earnings last quarter?: Proteon Therapeutics Inc (NASDAQ:PRTO) issued its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01.
What other stocks do shareholders of Proteon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Sierra Oncology (SRRA), Agile Therapeutics (AGRX), Biocept (BIOC), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Proteon Therapeutics' stock symbol?: Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."
What is Proteon Therapeutics' stock price today?: One share of PRTO stock can currently be purchased for approximately $3.47.
How much money does Proteon Therapeutics make?: Proteon Therapeutics (NASDAQ:PRTO) has a market capitalization of $76.96 million. The biopharmaceutical company earns $-20,730,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
How can I contact Proteon Therapeutics?: Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The official website for the company is www.proteontherapeutics.com. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at investor@proteontherapeutics.com.

This page (NASDAQ:PRTO) was last updated on 8/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms